A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4

Abstract

Although the primary end-point was not met in the intent-to-treat population, tozorakimab showed positive efficacy signals <i>versus</i> placebo in a subgroup of patients with COPD with a high risk of exacerbations.